Cutting edge: PD-1 regulates imiquimod-induced psoriasiform dermatitis through inhibition of IL-17A expression by innate γδ-low T cells

Journal of Immunology

Volumn 195, Issue 2, 2015, Pages 421-425

  Imai, Yasutomo ^a   Ayithan, Natarajan ^a   Wu, Xuesong ^a   Yuan, Ying ^a   Wang, Li ^a   Hwang, Sam T ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; INTERLEUKIN 17; PROGRAMMED DEATH 1 RECEPTOR; AMINOQUINOLINE DERIVATIVE; ANTIBODY; IL17A PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; PDCD1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EPIDERMIS HYPERPLASIA; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HISTOPATHOLOGY; IN VITRO STUDY; KERATINOCYTE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DERMATITIS; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; NEUTROPHIL; PATHOLOGY; SIGNAL TRANSDUCTION; TH17 CELL;

AMINOQUINOLINES; ANIMALS; ANTIBODIES; DERMATITIS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-17; KERATINOCYTES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHIL INFILTRATION; NEUTROPHILS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SIGNAL TRANSDUCTION; TH17 CELLS;

EID: 84936805511     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500448     Document Type: Article

References (24)

1. Okazaki, T., and T. Honjo. 2007. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19: 813-824.
2. Wolchok, J. D., H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, N. H. Segal, C. E. Ariyan, R. A. Gordon, K. Reed, et al. 2013. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369: 122-133.
3. Robert, C., G. V. Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier, J. C. Hassel, P. Rutkowski, C. McNeil, E. Kalinka-Warzocha, et al. 2015. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372: 320-330.
4. Ono Pharmaceutical and Bristol-Myers Squibb. 2014. Package insert of Opdivo (nivolumab). Available at: https://www.opdivo.jp/contents/pdf/open/tenpu.pdf (Japanese)
5. http://packageinserts.bms.com/pi/pi-opdivo.pdf (English).
6. Kubota, K., Y. Kamijima, T. Sato, N. Ooba, D. Koide, H. Iizuka, and H. Nakagawa. 2015. Epidemiology of psoriasis and palmoplantar pustulosis: A nationwide study using the Japanese national claims database. BMJ Open 5: e006450.
7. Nishimura, H., N. Minato, T. Nakano, and T. Honjo. 1998. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 10: 1563-1572.
8. Pedoeem, A., I. Azoulay-Alfaguter, M. Strazza, G. J. Silverman, and A. Mor. 2014. Programmed death-1 pathway in cancer and autoimmunity. Clin. Immunol. 153: 145-152.
9. Tsushima, F., H. Iwai, N. Otsuki, M. Abe, S. Hirose, T. Yamazaki, H. Akiba, H. Yagita, Y. Takahashi, K. Omura, et al. 2003. Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. Eur. J. Immunol. 33: 2773-2782.
10. Okiyama, N., and S. I. Katz. 2014. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes. J. Autoimmun. 53: 1-9.
11. + innate lymphocytes and gd T cells initiate psoriasiform plaque formation in mice. J. Clin. Invest. 122: 2252-2256.
12. Van Belle, A. B., M. de Heusch, M. M. Lemaire, E. Hendrickx, G. Warnier, K. Dunussi-Joannopoulos, L. A. Fouser, J. C. Renauld, and L. Dumoutier. 2012. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J. Immunol. 188: 462-469.
13. Cai, Y., X. Shen, C. Ding, C. Qi, K. Li, X. Li, V. R. Jala, H. G. Zhang, T. Wang, J. Zheng, and J. Yan. 2011. Pivotal role of dermal IL-17-producing gd T cells in skin inflammation. Immunity 35: 596-610.
14. + gd T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis. J. Immunol. 187: 5026-5031.
15. Mabuchi, T., T. P. Singh, T. Takekoshi, G. F. Jia, X. Wu, M. C. Kao, I. Weiss, J. M. Farber, and S. T. Hwang. 2013. CCR6 is required for epidermal trafficking of gd-T cells in an IL-23-induced model of psoriasiform dermatitis. J. Invest. Dermatol. 133: 164-171.
16. + congenic mouse substrain provides protection from dermatitis. Nat. Immunol. 14: 584-592.
17. Freeman, G. J., A. J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L. J. Fitz, N. Malenkovich, T. Okazaki, M. C. Byrne, et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192: 1027-1034.
18. Yoshiki, R., K. Kabashima, T. Honda, S. Nakamizo, Y. Sawada, K. Sugita, H. Yoshioka, S. Ohmori, B. Malissen, Y. Tokura, and M. Nakamura. 2014. IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing gd T cells. J. Invest. Dermatol. 134: 1912-1921.
19. Sumida, H., K. Yanagida, Y. Kita, J. Abe, K. Matsushima, M. Nakamura, S. Ishii, S. Sato, and T. Shimizu. 2014. Interplay between CXCR2 and BLT1 facilitates neutrophil infiltration and resultant keratinocyte activation in a murine model of imiquimod-induced psoriasis. J. Immunol. 192: 4361-4369.
20. + T cell responses. J. Immunol. 184: 4918-4925.
21. Marzec, M., Q. Zhang, A. Goradia, P. N. Raghunath, X. Liu, M. Paessler, H. Y. Wang, M. Wysocka, M. Cheng, B. A. Ruggeri, and M. A. Wasik. 2008. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc. Natl. Acad. Sci. USA 105: 20852-20857.
22. Sanderson, K., R. Scotland, P. Lee, D. Liu, S. Groshen, J. Snively, S. Sian, G. Nichol, T. Davis, T. Keler, et al. 2005. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23: 741-750.
23. Phan, G. Q., J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100: 8372-8377.
24. Helms, C., L. Cao, J. G. Krueger, E. M. Wijsman, F. Chamian, D. Gordon, M. Heffernan, J. A. Daw, J. Robarge, J. Ott, et al. 2003. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat. Genet. 35: 349-356.